Alterity Therapeutics to Present in MST Access Rare Diseases, Rich Returns Forum on 22 June 2023
21 June 2023 - 9:25PM
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the
Company”), a biotechnology company dedicated to developing disease
modifying treatments for neurodegenerative diseases, today
announced that David Stamler, M.D., Chief Executive Officer of
Alterity will present a corporate overview and participate in a
Q&A discussion at the MST Access Rare Diseases, Rich Returns
Forum on Thursday, 22 June 2023 at 10:30 a.m. AEST (Wednesday, 21
June 2023 at 5:30 p.m. Pacific Time).
A link to the live webinar may be accessed on
the Alterity website under the Investors section Events and
Presentations.
About Alterity Therapeutics
Limited
Alterity Therapeutics is a clinical stage
biotechnology company dedicated to creating an alternate future for
people living with neurodegenerative diseases. The Company’s lead
asset, ATH434, has the potential to treat various Parkinsonian
disorders and is currently being evaluated in two Phase 2 clinical
trials in Multiple System Atrophy. Alterity also has a broad drug
discovery platform generating patentable chemical compounds to
treat the underlying pathology of neurological diseases. The
Company is based in Melbourne, Australia, and San Francisco,
California, USA. For further information please visit the Company’s
web site at www.alteritytherapeutics.com.
Authorisation & Additional informationThis
announcement was authorized by David Stamler, CEO of Alterity
Therapeutics Limited.
Investor and Media Contacts:
AustraliaHannah
Howlettwe-aualteritytherapeutics@we-worldwide.com+61 450 648
064
U.S.Remy Bernarda
remy.bernarda@iradvisory.com+1 (415) 203-6386
Alterity Therapeutics (NASDAQ:ATHE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alterity Therapeutics (NASDAQ:ATHE)
Historical Stock Chart
From Apr 2023 to Apr 2024